Allison Berger
- Aging top 5%
- Hematology top 2%
- Multiple Myeloma Research and Treatments 9
- Oncology top 5%
- Peptidase Inhibition and Analysis 11
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 45
- Protein Degradation and Inhibitors 17
- Histone Deacetylase Inhibitors Research 6
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 7
-
- interferon and immune responses 6
-
- Chronic Lymphocytic Leukemia Research 6
- Co-authors
- Jie YuMark ManfrediLawrence R. DickJoshua M. KaplanAnne C. HartMark RolfeMichael A. MilhollenBret Bannerman
- Cited by
- AgingHematologyOncology
- Partner nations
- United StatesJapanCanada
In The Last Decade
Allison Berger
66 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 107
- Aging 84
- Hematology 452
- Oncology 779
- Molecular Biology 1.6k
- Cancer Research 241
Countries citing papers authored by Allison Berger
This map shows the geographic impact of Allison Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Berger more than expected).
Fields of papers citing papers by Allison Berger
This network shows the impact of papers produced by Allison Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Berger. The network helps show where Allison Berger may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Allison Berger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 7 | |
| 3 | 2023 | 8 | |
| 4 | 2023 | 17 | |
| 5 | 2022 | 10 | |
| 6 | 2021 | 4 | |
| 7 | 2021 | 10 | |
| 8 | 2021 | 18 | |
| 9 | 2016 | 16 | |
| 10 | 2015 | 162 | |
| 11 | 2015 | 139 | |
| 12 | 2015 | 10 | |
| 13 | 2015 | 47 | |
| 14 | 2013 | 89 | |
| 15 | 2013 | 58 | |
| 16 | 2013 | 22 | |
| 17 | 2011 | 32 | |
| 18 | 2010 | 409 | |
| 19 | Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer | 2007 | 1 |
| 20 | 1993 | 13 |
About Allison Berger
Allison Berger is a scholar working on Oncology, Hematology, Immunology, Molecular Biology and Cancer Research, having authored 69 papers that have together received 2.1k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (45 papers), Protein Degradation and Inhibitors (17 papers), Peptidase Inhibition and Analysis (11 papers), Multiple Myeloma Research and Treatments (9 papers), Cancer, Hypoxia, and Metabolism (7 papers), interferon and immune responses (6 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Histone Deacetylase Inhibitors Research (6 papers). The work is most often cited by research in Aging (84 citations), Hematology (452 citations), Oncology (779 citations), Molecular Biology (1.6k citations) and Cancer Research (241 citations). Allison Berger has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Jie Yu, Mark Manfredi, Lawrence R. Dick, Joshua M. Kaplan, Anne C. Hart, Mark Rolfe, Michael A. Milhollen, Bret Bannerman, Paul Hales and Erik Kupperman. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.